Filter Results:
(1,248)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
Show Results For
- All HBS Web
(1,248)
- People (5)
- News (172)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (759)
- 11 Oct 2011
- Working Paper Summaries
US Healthcare Reform and the Pharmaceutical Industry
- January 2021 (Revised June 2021)
- Case
Hester Pharmaceuticals (A): A Pricing Dilemma
By: Dante Roscini and John Masko
In August 2019, the leadership of Hester Pharmaceuticals (Hester) had a problem. Italy promised to be a key market for their new breakthrough oncology drug Akrozumab, but for almost two years, its single-payer healthcare system had been unable to agree with Hester on a... View Details
Keywords: Macroeconomics; Trade; Price; Global Range; Global Strategy; Globalized Markets and Industries; Health Care and Treatment; Patents; Monopoly; Negotiation; Business and Government Relations; Risk and Uncertainty; Human Needs; Business Strategy; Commercialization; Pharmaceutical Industry; Italy
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (A): A Pricing Dilemma." Harvard Business School Case 721-001, January 2021. (Revised June 2021.)
- February 1998 (Revised May 1998)
- Case
Merck-Medco: Vertical Integration in the Pharmaceutical Industry
By: V. Kasturi Rangan and Marie Bell
Records the analyses and actions taken by Merck Pharmaceuticals in its acquisition of Medco, a channel intermediary (called "pharmacy benefit manager"). While many of its competitors seem to be faring poorly, Merck seems to have managed the Medco integration superbly. View Details
Keywords: Vertical Integration; Organizational Change and Adaptation; Competitive Strategy; Marketing Channels; Mergers and Acquisitions; Pharmaceutical Industry
Rangan, V. Kasturi, and Marie Bell. "Merck-Medco: Vertical Integration in the Pharmaceutical Industry." Harvard Business School Case 598-091, February 1998. (Revised May 1998.)
- September 2021 (Revised October 2022)
- Supplement
Hester Pharmaceuticals (B): Securing Supply
By: Dante Roscini and John Masko
Supplements the (A) case. In late 2020, demand for Hester Pharmaceutical’s (Hester’s) breakthrough oncology drug Akrozumab was outstripping the company’s most optimistic projections. In order to increase manufacturing capacity and meet the demand, Hester was... View Details
Keywords: COVID-19 Pandemic; Cost vs Benefits; Trade; Supply Chain; Global Strategy; Buildings and Facilities; Operations; Health Care and Treatment; Demand and Consumers; Global Range; Globalized Markets and Industries; Pharmaceutical Industry; Italy; China; United States; Germany
Roscini, Dante, and John Masko. "Hester Pharmaceuticals (B): Securing Supply." Harvard Business School Supplement 722-009, September 2021. (Revised October 2022.)
- June 1994 (Revised March 1995)
- Case
Kurt Landgraf and Du Pont Merck Pharmaceutical Co. (A)
Kurt Landgraf, newly named CEO of Du Pont Merck Pharmaceutical Co., addresses complaints of discrimination from African-American scientists in R&D during significant downsizing and dramatic changes within the pharmaceutical industry. View Details
Keywords: Prejudice and Bias; Race Characteristics; Gender Characteristics; Diversity Characteristics; Conflict and Resolution; Pharmaceutical Industry
Gentile, Mary C., and Sarah Gant. "Kurt Landgraf and Du Pont Merck Pharmaceutical Co. (A)." Harvard Business School Case 394-202, June 1994. (Revised March 1995.)
- July 2002 (Revised December 2002)
- Case
Phase Two: The Pharmaceutical Industry Responds to AIDS
By: Debora L. Spar
Describes how major pharmaceutical firms changed their strategy and pricing policies in the years 2000 to 2002 to respond to the growing AIDS epidemic in Africa. View Details
Keywords: International Finance; Health Pandemics; Corporate Social Responsibility and Impact; Pharmaceutical Industry; Africa
Spar, Debora L., and Nick Bartlett. "Phase Two: The Pharmaceutical Industry Responds to AIDS." Harvard Business School Case 703-005, July 2002. (Revised December 2002.)
- January 1990 (Revised January 1993)
- Teaching Note
International Pharmaceuticals Inc., Teaching Note
By: W. Carl Kester
Keywords: Pharmaceutical Industry
- August 2007
- Teaching Note
Teva Pharmaceutical Industries, Ltd (TN)
By: Tarun Khanna and Krishna G. Palepu
Teaching note to 707441. View Details
- September 1988
- Background Note
Note on the Pharmaceutical Industry
Keywords: Pharmaceutical Industry
Herzlinger, Regina E. "Note on the Pharmaceutical Industry." Harvard Business School Background Note 189-076, September 1988.
- August 1994
- Teaching Note
Yamanouchi Pharmaceutical Co., Ltd. TN
By: Robin Cooper and Robert S. Kaplan
Keywords: Pharmaceutical Industry
- February 2003 (Revised April 2004)
- Case
Pharmaceutical Industry, The: Challenges in the New Century
By: Stephen P. Bradley and James Weber
Provides a broad overview of the numerous internal and external forces that were driving change in the global pharmaceutical industry in 2003. These forces--including downward price pressures, political and social pressures, increased development costs, new... View Details
Keywords: Business Model; Change; Cost; Price; Globalization; Government and Politics; Brands and Branding; Industry Growth; Society; Competition; Consolidation; Technology; Pharmaceutical Industry
Bradley, Stephen P., and James Weber. "Pharmaceutical Industry, The: Challenges in the New Century." Harvard Business School Case 703-489, February 2003. (Revised April 2004.)
- March 1993 (Revised May 1998)
- Teaching Note
ImmuLogic Pharmaceutical Corporation (Series) TN
By: Josh Lerner
Teaching Note for (9-293-066--071) and (9-293-087). View Details
Keywords: Pharmaceutical Industry
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (D): Hatch-Waxman Change
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (D): Hatch-Waxman Change." Harvard Business School Supplement 806-067, January 2006. (Revised May 2007.)
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (B): Merger Decision
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (B): Merger Decision." Harvard Business School Supplement 806-065, January 2006. (Revised May 2007.)
- February 2002 (Revised March 2002)
- Case
India's Intellectual Property Rights Regime and the Pharmaceutical Industry
In 1970, the Indian government significantly revised its patent law, Patents and Design Act of 1911. The 1911 act was enacted when India was a colony of Great Britain, and it was controversial because it led to the total dominance of India's pharmaceutical market by... View Details
Huang, Yasheng, and Hal Hogan. "India's Intellectual Property Rights Regime and the Pharmaceutical Industry." Harvard Business School Case 702-039, February 2002. (Revised March 2002.)
- 30 Mar 2012
- HBS Seminar
Matthew W. Emmens, Executive Chairman,Vertex Pharmaceuticals
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B3): Katherine Kirk." Harvard Business School Supplement 293-069, October 1992. (Revised March 1993.)
- October 1992 (Revised March 1993)
- Supplement
ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter
By: Josh Lerner
Supplements the (A) case. View Details
Keywords: Pharmaceutical Industry
Lerner, Josh. "ImmuLogic Pharmaceutical Corporation (B1): Malcolm Gefter." Harvard Business School Supplement 293-067, October 1992. (Revised March 1993.)
- January 2006 (Revised May 2007)
- Supplement
Endo Pharmaceuticals (F): Appeals Court Ruling
By: Richard G. Hamermesh and Brian DeLacey
Hamermesh, Richard G., and Brian DeLacey. "Endo Pharmaceuticals (F): Appeals Court Ruling." Harvard Business School Supplement 806-082, January 2006. (Revised May 2007.)